News
AMRN
--
0.00%
--
'Amarin: 85% Of Doctors Polled At AHA Conference Intend To Prescribe Vascepa' -Seeking Alpha Blog Post From Contributor
https://seekingalpha.com/article/4222150-amarin-85-percent-doctors-polled-aha-conference-intend-prescribe-vascepa
Benzinga · 11/19 21:47
Bvf Inc Buys Galapagos NV, Amarin Corp PLC, Aadi Bioscience Inc, Sells Merus NV, argenx SE, ...
GuruFocus News · 11/17 00:38
Amarin Posts Encouraging Vascepa Data In Patients With Peripheral Artery Disease
Benzinga · 11/16 16:35
Amarin jumps after activist Sarissa discloses stake in 13-F filing
Amarin (NASDAQ:AMRN) rose 11% after activist investor Sarissa Capital disclosed a new stake in the company. Sarissa unveiled owning 8.5M shares, or a 2.15%, stake in Amarin, according to a 13-F filing.
Seekingalpha · 11/16 15:52
The Daily Biotech Pulse: Kezar Jumps On Data, Biogen R&D Chief To Retire, Molecular Partners Wilts On COVID Trial Disappointment
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 11/16 13:30
Amarin Reports Overview of Latest Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) and Eicosapentaenoic Acid (EPA) Presented at the American Heart Association Scientific Sessions 2021
VASCEPA/VAZKEPA found in prespecified and post hoc analyses to reduce total ischemic events by 32% in patients with prior PAD...
Globe Newswire · 11/16 12:00
Amarin Highlights Subgroup Data From REDUCE-IT Shows Benefits Of VASCEPA/VAZKEPA In Patients With Prior Peripheral Artery Disease Presented At Oral Session Presentation For American Heart Association Scientific Sessions Nov. 13-15
VASCEPA/VAZKEPA found in prespecified and post hoc analyses to reduce total ischemic events by 32% in patients with prior PAD DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation
Benzinga · 11/15 21:35
Amarin Reports Subgroup Data from REDUCE-IT® Highlighting Benefits of VASCEPA®/VAZKEPA (Icosapent Ethyl) in Patients with Prior Peripheral Artery Disease (PAD) Presented in Rapid Fire Oral Session Presentation at the American Heart Association Scientific Sessions 2021
VASCEPA/VAZKEPA found in prespecified and post hoc analyses to reduce total ischemic events by 32% in patients with prior PADDUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that ...
GlobeNewswire · 11/15 21:30
Amarin to Present at Two Upcoming Investor Conferences
DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail,...
Globe Newswire · 11/11 12:00
Latest Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) to be Presented at American Heart Association Scientific Sessions 2021
Amarin-Supported Research and Analyses from International Academic Collaborators to Be Featured in Three Presentations Also Featuring Virtual Exhibit Booth, Digital Product Theater and On-Line Continuing Medical Education Programming DUBLIN, Ireland and BR...
GlobeNewswire · 11/08 12:00
Amarin (NASDAQ:AMRN shareholders incur further losses as stock declines 9.4% this week, taking three-year losses to 80%
It's not possible to invest over long periods without making some bad investments. But really big losses can really...
Simply Wall St. · 11/05 10:37
Amarin Corp Earnings Perspective: Return On Capital Employed
Amarin Corp (NASDAQ:AMRN) brought in sales totaling $142.04 million during Q3 according to data provided by Benzinga Pro. However, earnings decreased 249.01%, resulting in a loss of $13.07 million.
Benzinga · 11/03 16:01
Amarin (AMRN) Q3 Earnings Top, Vascepa Sales Decline Y/Y
Zacks.com · 11/03 15:17
BRIEF-Amarin Corporation Reports Quarterly Net Loss Per Share Of $0.03
reuters.com · 11/03 14:32
Amarin EPS beats by $0.01, misses on revenue
Amarin (NASDAQ:AMRN): Q3 Non-GAAP EPS of -$0.03 beats by $0.01; GAAP EPS of -$0.03 in-line. Revenue of $142.04M (-9.2% Y/Y) misses by $19.25M. Press Release As of September 30, 2021, Amarin
Seekingalpha · 11/03 10:03
Amarin Reports Third Quarter 2021 Financial Results and Provides Business Update
Launched VAZKEPA in Germany with Multiple European Country Launches Expected in 2022 Introduced New Go-to-Market Strategy in U.S. to Enhance Awareness and Drive Demand for VASCEPA® Plans for Regulatory Filings and Approvals of VASCEPA in Several Additional...
GlobeNewswire · 11/03 10:00
Amarin Q3 Adjusted Profit Rises, Revenue Declines
MT Newswires · 11/03 06:46
-- Earnings Flash (AMRN) AMARIN CORPORATION Posts Q3 Revenue $142M, vs. Street Est of $161.3M
MT Newswires · 11/03 06:05
Do Hedge Funds Love Amarin Corporation plc (AMRN)?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds’ and successful investors’ positions as of the end of the second qu...
Insider Monkey · 10/25 16:46
Amarin to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company will host a conference call with members of Amarin’s senior management team to discuss the Company's third quarte...
GlobeNewswire · 10/20 11:05
Webull provides a variety of real-time AMRN stock news. You can receive the latest news about Amarin through multiple platforms. This information may help you make smarter investment decisions.
About AMRN
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company's lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.